CytomX Reports Significant Progress in Phase 1 Study of Varseta-M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy CTMX?
Source: Yahoo Finance
- Clinical Trial Results: CytomX Therapeutics reported a 32% confirmed overall response rate at 10 mg/kg and 20% at 8.6 mg/kg for Varseta-M in late-line colorectal cancer, indicating a significant market opportunity for the drug.
- Survival Improvement: Progression-free survival (PFS) estimates have improved to 6.8 to 7.1 months, demonstrating enhanced efficacy that may attract increased investor interest and confidence in the drug's potential.
- Adverse Event Management: The incidence of Grade 3 diarrhea has been reduced to 10% through optimized prophylactic strategies, which not only improves patient treatment experiences but also lays a solid foundation for future clinical applications.
- Market Outlook: CytomX plans to advance Varseta-M into its first registrational study, aiming for a potential multibillion-dollar market opportunity in the U.S. by 2040, reflecting the company's confidence and strategic foresight regarding the drug's market positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTMX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTMX
Wall Street analysts forecast CTMX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.520
Low
6.00
Averages
9.00
High
10.00
Current: 4.520
Low
6.00
Averages
9.00
High
10.00
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CytomX Therapeutics Price Target Raised by Analysts
- Analyst Target Increases: Guggenheim raised its price target for CytomX Therapeutics from $10 to $15 while maintaining a ‘Buy’ rating, reflecting confidence in the company's growth prospects.
- Significant Market Opportunity: Jefferies analysts see a market opportunity of up to $5 billion for Varseta-M in late-line metastatic colorectal cancer, indicating the drug's substantial potential in the treatment landscape.
- Optimistic Trial Data: CytomX's early-stage trial data for Varseta-M revealed a 32% response rate at higher doses, with manageable side effects, further bolstering market confidence in the drug's efficacy.
- FDA Engagement Plans: CytomX plans to engage with the FDA mid-year to align on a potential registrational study, demonstrating the company's proactive approach to advancing Varseta-M towards market approval.
See More
CytomX Therapeutics Prices Public Offering
- Public Offering Pricing: CytomX Therapeutics announced the pricing of its public offering of securities, although specific amounts were not disclosed, this move aims to provide funding for the company's future research and operations.
- Use of Funds: The offering is expected to supply the necessary capital to drive innovation in antibody drug development, particularly in cancer treatment solutions.
- Market Reaction: The market's response to this offering remains unclear, and investors should monitor subsequent market dynamics and the company's future financial performance.
- Strategic Implications: Through this public offering, CytomX aims to strengthen its capital structure and enhance its market competitiveness to secure a more advantageous position in the biopharmaceutical industry.
See More
CytomX Launches $250 Million Public Offering
- Offering Size: CytomX Therapeutics announced a public offering of 45.99 million shares at $5.30 each, with total gross proceeds estimated at $250 million, reflecting the company's proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase an additional 1.18 million shares, enhancing investor participation and financing flexibility, which is expected to improve the company's liquidity.
- Underwriter Option: CytomX has granted its underwriters a 30-day option to purchase an additional 7.08 million shares at the same public offering price, a strategy that could provide further financial support for future project developments.
- Use of Proceeds: The proceeds from this offering will be allocated towards the development of Varseta-M and other pipeline programs, as well as capital expenditures, working capital, and general corporate purposes, demonstrating the company's strategic focus on future growth.
See More
CytomX Announces Pricing of Public Offering
- Public Offering Pricing: CytomX Therapeutics announced a public offering of 45.99 million shares at $5.30 each, expecting gross proceeds of $250 million, indicating strong market demand for its stock.
- Use of Proceeds: The company intends to utilize the net proceeds for the continued development of Varseta-M and other pipeline programs, as well as for capital expenditures and general corporate purposes, highlighting its commitment to drug development.
- Underwriter Options: CytomX granted underwriters a 30-day option to purchase an additional 7.08 million shares, enhancing liquidity and attractiveness of its stock in the market.
- Financial Performance Overview: In 2025, the company reported a net loss of $17.37 million with total revenue declining to $76.20 million; however, it ended the year with $137.1 million in cash, projecting a cash runway into Q2 2027, demonstrating financial resilience.
See More
CytomX Launches $250 Million Public Offering
- Offering Size: CytomX Therapeutics has announced a $250 million underwritten public offering aimed at funding the development of Varseta-M and other pipeline programs, with remaining proceeds allocated for capital expenditures and general corporate purposes.
- Stock Price Reaction: Following the offering announcement, CTMX shares fell by 2.22% to $6.60, indicating a cautious market response that may affect investor confidence in the company's future prospects.
- Financial Performance: CytomX reported a net loss of $17.3 million for 2025, a stark contrast to a net income of $31.8 million in 2024, highlighting significant challenges in revenue generation and profitability.
- Cash Flow Position: As of the end of 2025, CytomX had $137.1 million in cash and cash equivalents, projecting a cash runway into the second quarter of 2027, indicating a degree of financial flexibility in managing ongoing operations.
See More
CytomX Launches $250 Million Stock Offering to Fund Cancer Drug Development
- Funding Initiative: CytomX has launched a $250 million stock offering, with the potential to raise an additional $37.5 million, aimed at financing the development of its lead cancer drug Varseta-M and other pipeline projects, reflecting the company's confidence in future treatment options.
- Clinical Trial Results: Varseta-M demonstrated a 32% response rate in metastatic colorectal cancer trials, maintaining disease stability for approximately 7 months, indicating significant potential in cancer control and the possibility of changing treatment standards.
- Financial Performance: Despite reporting a fourth-quarter loss of $0.22 per share, exceeding the expected $0.09, and revenue of $663,000 falling short of the $7.9 million estimate, CytomX's cash reserves are projected to last until Q2 2027, showcasing some financial resilience.
- Market Reaction: CytomX shares surged over 44% on Monday to close at $6.75, and although the stock offering raised dilution concerns, analysts remain optimistic about the strong cancer data, suggesting a potential upside of 152% in the future.
See More
CytomX Therapeutics Price Target Raised by Analysts
- Analyst Target Increases: Guggenheim raised its price target for CytomX Therapeutics from $10 to $15 while maintaining a ‘Buy’ rating, reflecting confidence in the company's growth prospects.
- Significant Market Opportunity: Jefferies analysts see a market opportunity of up to $5 billion for Varseta-M in late-line metastatic colorectal cancer, indicating the drug's substantial potential in the treatment landscape.
- Optimistic Trial Data: CytomX's early-stage trial data for Varseta-M revealed a 32% response rate at higher doses, with manageable side effects, further bolstering market confidence in the drug's efficacy.
- FDA Engagement Plans: CytomX plans to engage with the FDA mid-year to align on a potential registrational study, demonstrating the company's proactive approach to advancing Varseta-M towards market approval.
See More
CytomX Therapeutics Prices Public Offering
- Public Offering Pricing: CytomX Therapeutics announced the pricing of its public offering of securities, although specific amounts were not disclosed, this move aims to provide funding for the company's future research and operations.
- Use of Funds: The offering is expected to supply the necessary capital to drive innovation in antibody drug development, particularly in cancer treatment solutions.
- Market Reaction: The market's response to this offering remains unclear, and investors should monitor subsequent market dynamics and the company's future financial performance.
- Strategic Implications: Through this public offering, CytomX aims to strengthen its capital structure and enhance its market competitiveness to secure a more advantageous position in the biopharmaceutical industry.
See More
CytomX Launches $250 Million Public Offering
- Offering Size: CytomX Therapeutics announced a public offering of 45.99 million shares at $5.30 each, with total gross proceeds estimated at $250 million, reflecting the company's proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase an additional 1.18 million shares, enhancing investor participation and financing flexibility, which is expected to improve the company's liquidity.
- Underwriter Option: CytomX has granted its underwriters a 30-day option to purchase an additional 7.08 million shares at the same public offering price, a strategy that could provide further financial support for future project developments.
- Use of Proceeds: The proceeds from this offering will be allocated towards the development of Varseta-M and other pipeline programs, as well as capital expenditures, working capital, and general corporate purposes, demonstrating the company's strategic focus on future growth.
See More
CytomX Announces Pricing of Public Offering
- Public Offering Pricing: CytomX Therapeutics announced a public offering of 45.99 million shares at $5.30 each, expecting gross proceeds of $250 million, indicating strong market demand for its stock.
- Use of Proceeds: The company intends to utilize the net proceeds for the continued development of Varseta-M and other pipeline programs, as well as for capital expenditures and general corporate purposes, highlighting its commitment to drug development.
- Underwriter Options: CytomX granted underwriters a 30-day option to purchase an additional 7.08 million shares, enhancing liquidity and attractiveness of its stock in the market.
- Financial Performance Overview: In 2025, the company reported a net loss of $17.37 million with total revenue declining to $76.20 million; however, it ended the year with $137.1 million in cash, projecting a cash runway into Q2 2027, demonstrating financial resilience.
See More
CytomX Launches $250 Million Public Offering
- Offering Size: CytomX Therapeutics has announced a $250 million underwritten public offering aimed at funding the development of Varseta-M and other pipeline programs, with remaining proceeds allocated for capital expenditures and general corporate purposes.
- Stock Price Reaction: Following the offering announcement, CTMX shares fell by 2.22% to $6.60, indicating a cautious market response that may affect investor confidence in the company's future prospects.
- Financial Performance: CytomX reported a net loss of $17.3 million for 2025, a stark contrast to a net income of $31.8 million in 2024, highlighting significant challenges in revenue generation and profitability.
- Cash Flow Position: As of the end of 2025, CytomX had $137.1 million in cash and cash equivalents, projecting a cash runway into the second quarter of 2027, indicating a degree of financial flexibility in managing ongoing operations.
See More
CytomX Launches $250 Million Stock Offering to Fund Cancer Drug Development
- Funding Initiative: CytomX has launched a $250 million stock offering, with the potential to raise an additional $37.5 million, aimed at financing the development of its lead cancer drug Varseta-M and other pipeline projects, reflecting the company's confidence in future treatment options.
- Clinical Trial Results: Varseta-M demonstrated a 32% response rate in metastatic colorectal cancer trials, maintaining disease stability for approximately 7 months, indicating significant potential in cancer control and the possibility of changing treatment standards.
- Financial Performance: Despite reporting a fourth-quarter loss of $0.22 per share, exceeding the expected $0.09, and revenue of $663,000 falling short of the $7.9 million estimate, CytomX's cash reserves are projected to last until Q2 2027, showcasing some financial resilience.
- Market Reaction: CytomX shares surged over 44% on Monday to close at $6.75, and although the stock offering raised dilution concerns, analysts remain optimistic about the strong cancer data, suggesting a potential upside of 152% in the future.
See More
